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Abstract
Percutaneous transluminal angioplasty (PTA) is the mainstay treatment for central vein stenosis. However, the recurrent rate of the stenotic lesion after PTA remains high.
Thus, we ran a review found on some databases. Out of thirteen articles, five articles were eligible and reviewed. Drug-coated balloon angioplasty, plain old balloon
angioplasty, percutaneous transluminal angioplasty, and stenting angioplasty were discussed regarding the outcomes with a focus on interest to prevent the stenosis.
Key words: Percutaneous transluminal angioplasty, central vein stenosis, restenosis

Introduction
Central vein stenosis (CVS) is a narrowed blood vessel due to central
venous catheter usage in hemodialysis patients with end-stage renal
disease (ESRD).1 ESRD prevalence in Indonesia is 20,000 cases per
year based on 2012 data.2 Some studies showed that CVS incidence is
19% in patients with central venous catheters and up to 50%
prevalence.3-6 The actual prevalence and incidence were hard to find
because of the challenging diagnosis as the patients usually remain
asymptomatic. In dr. Cipto Mangunkusumo hospital, 38 cases of CVS
were identified and managed with a technical success rate reaching
85.3% from 2013 to 2016.7
Percutaneous transluminal angioplasty (PTA) is the mainstay treatment
for CVS. Over the years, many findings suggest that PTA provides
efficacy in managing CVS. However, the recurrent rate of the stenotic
lesion after PTA remains high. Various studies addressed histological
changes and elastic recoil changes, purposed to identify the underlying
etiology. An intravascular stent developed as a measure to prevent
recurrent stenosis after PTA. A review addressed to find what is
unknown regarding the outcomes of this PTA procedure.3,4,5,8
Central vein stenosis and its management
CVS might develop asymptomatically despite leading to long-term
complications such as inadequate hemodialysis delivery due to
recirculation, impaired maturation of arteriovenous fistula, long-term
patency decrease, and superior vena cava syndrome.1 A condition
referred to the most frequent complication of catheter placement in the
central vein. Risk factors for CVS development include the location, the
material, the interval between the placement and the onset of symptoms,
stenosis location, and long catheter placement (more than six weeks
duration).3,4,7 In symptomatic cases, the diagnosis may be instituted
clinically. The arm is swelling as to the chief complaint, along with
collateral blood vessels finding. In asymptomatic cases, the diagnosis is

instituted by venography. Venography is superior to Doppler ultrasound
and remains a gold standard in evaluating venous abnormality.9
There are modalities in CVS treatment, either it's endovascular
intervention, open surgery, medication, and palliative treatment. The
treatments consist of access abandonment, thrombolysis therapy,
angioplasty, and bypass operation. Access abandonment is done by
ligation of venous access that results in immediate symptoms free. The
anatomical pathology is not corrected with this method, and there might
be a problem with venous access placement in the future. Thrombolysis
is referred to as a treatment for total vein obstruction due to acute
thrombosis. The treatment usually proceeds with angioplasty.
Angioplasty may be carried out with or without a stent.10,11 The
angioplasty remains as the treatment of choice by The Kidney Disease
Outcomes Quality Initiative (K/DOQI) Guideline 20.12 The angioplasty
is used for diagnostic purposes and therapy per se by injecting contrast
and expanding the intravenous balloon. Percutaneous angioplasty
showed a high success rate of 70-90%. Bypass procedure is not
recommended since the method followed by high postoperative
mortality and morbidity.9We ran a review enrolling studies found in
literature search from databases (Cochrane, SCOPUS, PubMed, and
EBSCO) in accordance with PRISMA protocol. Out of 13 relevant
articles, five articles were eligible.
Meta-analysis of Kennedy et al. (2018) regarding drug-coated balloon
angioplasty (DCBA) and plain old balloon angioplasty (POBA)
enrolled twelve studies on 908 patients. The study concerned about
patency outcome after DCBA in the hemodialysis circuit, the patency
target lesion in arteriovenous fistula (AVF), arteriovenous graft (AVG),
and CVS. DCBA showed better outcomes than POBA with a higher
pooled patency percentage for a stenotic lesion with AVF. Pooled
patency outcome showed indifferent findings between DCBA and
POBA for CVS in hemodialysis patients.13
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Table 1. Subject Characteristics
Articles

Year

Study Design

Intervention

Kennedy et al.13

2019

Meta-analysis

Drug-coated balloon angioplasty (DCBA) vs. plain old
balloon angioplasty (POBA)

1a

Quartet et al.14

2016

Retrospective Cohort

Percutaneous transluminal angioplasty (PTA) vs. bare
metal stent vs. stent-graft

2b

2009

Retrospective Cohort

Percutaneous transluminal angioplasty (PTA) vs.
percutaneous transluminal stenting (PTS)

2b

Surowiec et al.15

2004

Retrospective Cohort

Percutaneous transluminal angioplasty

2b

Bakken et al.5

2007

Retrospective Cohort

Percutaneous transluminal angioplasty (PTA) vs.
percutaneous transluminal stenting (PTS)

2b

Ozer et al.4

A study by Quartet et al. focused on percutaneous transluminal
angioplasty (PTA) compared with bare-metal stent and stent graft. The
outcomes of interest were restenosis occurrence, primary patency rate,
and assisted patency rate. Primary patency, restenosis risk, and the need
for reintervention were significantly better in stent-graft than bare-metal
stent and PTA. A significant difference between each technique was not
shown in primary assisted patency.14 Another retrospective cohort study
by Oyzer et al. focused on the outcomes of vein intervention, primary
patency, and assisted primary patency duration in PTA and PTS. The
primary patency of PTA was significantly better than PTS. Meanwhile,
APP was equivalent in both methods. It was found that PTS prolong
vein patency that already refractory from PTA.4
The study by Surowiec et al. on percutaneous transluminal angioplasty
aimed to find the initial technical success rate, primary patency rate,
assisted patency rate of PTA. Such a study showed that PTA’s initial
technical success rate was 89%; primary patency rate in 1, 6, 12, and 24
months consecutively were 85, 55, 43, and 0%; assisted patency rate at
the same time point are 80, 80, 80, and 64%, respectively.15
The study by Bakken et al., who analyze primary patency rate, assisted
primary patency, hemodialysis access survival duration in PTA and
PTS, found that primary patency rate and APP rate between PTA and
PTS were not significantly different. Hemodialysis access survival
duration in an ipsilateral vein between PTA and PTS is equivalent.5
The outcomes of PTA are classified into two major categories,
radiological and clinical outcomes. Radiological outcomes are marked
by primary patency and assisted primary patency (APP). Four studies
discussed the primary patency rate of PTA procedures.5,6,10,11
According to Barret et al., which conducted a study on 125 hemodialysis
patients with CVS, PTA had primary patency rates of 90%, 83%, 77%,
and 47% at 3,6, 12, and 24 months respectively.5
The study of Quaretti et al. showed a similar outcome, and the rest
literature revealed the same trend with a lower primary patency rate.10
The overall primary patency rate ranged between 70-90% in three
months after PTA and about 40% in two years.5,6,13,14 The other
radiological outcome assisted primary patency (APP) rate, showed
slightly better rates than the primary patency. Clinical outcomes for PTA
showed outstanding performance. PTA was shown to be an effective
means of managing signs and symptoms caused by CVS with relatively
minor complications. The same study by Quaretti et al. indicates
declined venous patency and clinical signs will dissipate between 24–48
hours after PTA.14

LoE

Even though the percutaneous transluminal angiography success rate
was excellent, the threat of restenosis was still quite high. All the cohort
studies in our review studied the primary patency rate, which was part of
the radiological outcome. The average primary patency rate was about
90% in three months after the procedure and about 40% in two years.
Primary patency was defined as central vein patency duration before
restenosis without other procedures besides initial intervention.
Restenosis was highlighted because it would affect hemodialysis
treatment by impairing adequate blood flow. Meanwhile, the other
radiological outcome, assisted primary patency (APP) rate was slightly
higher than the primary patency rate. This finding might be possible
because other interventions were performed in APP, which leads to
widening lumen diameter resulting higher patency. 3,4,14,15
Several factors might take part in restenosis after the endovascular
intervention of CVS. Those are physiology and anatomy differences
between artery and vein, prolong hemodynamic stress, recurrent
vascular leakage, uremia, and endothelial dysfunction.16 However, the
role of each factor in restenosis is still unknown. Further studies should
be made to identify significant factors contributing to restenosis and how
to interfere with those factors. The patient's age had been known as a
non-contributing factor to restenosis after PTA placement in a study
conducted by the vascular surgery center in Russia. The subject was
assigned into two age groups, <60 years old and >60 years. Between the
two groups, it was found that PTA success and primary patency rates
were not significantly different.17
Clinical outcomes for PTA showed excellent performance with minimal
complications. There were relatively minor complications following the
PTA placement. Ruptured venous membrane, extremities embolism,
and post-procedural mortality were not encountered in reviewed
publications. Hematoma in venous access site and minimal
extravasation was found in one subject and handled by nitinol stent
placement.3 Meanwhile, another article reported subcutaneous bleeding
in one patient that was managed conservatively.14 The minimal
complications of PTA were adding significant value as the mainstay
treatment for CVS.The use of drug-coated balloon angioplasty (DCBA)
as an alternative treatment from plain old balloon angioplasty (POBA)
improved the primary patency rate of PTA. A meta-analysis study found
that DCBA was superior to POBA in treating stenosis with
arteriovenous fistula. However, DCBA was substantially indifferent
from POBA in regular CVS patients regarding primary patency,
complications, and mortality rate.13
Another publication identified different parameters to evaluate PTA
outcomes. PTA increases blood flow rate up to 111 mL/minute in
13
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vascular access after its placement. In addition, the clinical parameter
was also stated. PTA successfully subside clinical sign of CVS that
occurs in 96% patients although the symptoms might regain later.18

3.

4.

Stenting and angioplasty
Percutaneous transluminal stenting (PTS) was an alternative treatment
to manage recurrent SCV lesions or stenotic lesions that could not be
patented using PTA. Percutaneous transluminal stenting (PTS) consists
of various techniques, including bare-stent, graft-stent, and drug-coated
stent. In a retrospective cohort study, PTA primary patency and APP
have shown better outcomes than PTS.14 Meanwhile, the contrary result
was seen in another retrospective cohort study.4 The primary patency
and APP were not statistically different between PTS and PTA.
Guideline 20 of K/DOQI recommends PTS placement for elastic
lesions recurring within three months.12 In another publication, stent
placement is considered if recurrent stenosis occurs two times within
two months after PTA. Other indications include significant vein
perforation after PTA include conditions such as recoil of central vein,
significant residual stenosis, contralateral circulation with significant
gradient pressure, and iatrogenic perforation after angioplasty.4
PTS plays no role in prolonging the patency rate. In addition, it will lead
to more intervention central vein. The reason was related to impaired
vein condition due to former intervention. These findings were not
supporting PTS as the primary intervention for de novo CVS. Therefore,
PTS was indicated in CVS patients with resistance lesion to PTA
treatment or recurrent lesion. Stenting could be used right after PTA
placement but would not add up the patency success rate. The major
shortcoming of PTS was the overlapping of the stent with the internal
jugular vein and the contralateral part of the brachiocephalic vein. This
condition would inhibit catheter insertion entry when access failure
occurred. Another complication that might arise was intracranial
hypertension in intra-stent stenosis that affects the contralateral part of
the brachiocephalic or superior cava vein. Wallstent and nitinol-based
memotherm stent are the most used stent variant.19

5.

6.

7.

8.
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10.

11.

12.
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Summary
PTA is a relatively safe and effective modality for treating CVS with a
high success rate, minimal complications, and satisfactory radiology and
clinical outcome. The radiological outcomes of primary patency and
assisted primary patency was slightly varied but overall showed decent
results. However, restenosis might occur 1-2 years after intervention
with a high recurrent rate. If a stenotic lesion becomes recurrent, PTS
could be performed as an alternative. Several methods have been
developed to prevent restenosis. Further study is needed to develop an
endovascular technique that will increase the patency success rate and
prolong the patency duration in CVS.
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